transdermal systems Archives - AMW website

9. November 2021

AMW and AdhexPharma announce strategic partnership for transdermal delivery systems

Today a strategic partnership between AMW GmbH and AdhexPharma SAS on AMW’s transdermal delivery systems technology platform and product portfolio was announced, combining the strengths of both companies in the field of TDS. Under the partnership, AMW will focus on development, marketing authorization and licensing of novel transdermal delivery systems. AdhexPharma will focus on the commercial manufacturing and lifecycle management of the products. AdhexPharma will take over the manufacturing equipment and the IP for AMW’s products Buprenorphine and Rivastigmine and following a transition phase of up to 30 months the contract manufacturing of these Products from AMW.

2. May 2011

Obtaining unrestricted manufacturing permission for transdermal systems and drug implants

Type of inspection: General GMP inspection in accordance with Section 64 of the German Medicines Act (AMG), the provisions of the German Medicines and Drug Manufacturing Ordinance (AMWHV) and the EC-GMP Guide for the Acceptance of the New Manufacturing Rooms of AMW GmbH for the Production of Transdermal Systems, Verification of Systems for the Production of Clinical Test Samples and Manufacture of Market Goods for The Products: Transdermal Systems and Implants and for obtaining manufacturing authorisation for Market Goods.